HK1248218A1 - 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物 - Google Patents

作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物

Info

Publication number
HK1248218A1
HK1248218A1 HK18107567.8A HK18107567A HK1248218A1 HK 1248218 A1 HK1248218 A1 HK 1248218A1 HK 18107567 A HK18107567 A HK 18107567A HK 1248218 A1 HK1248218 A1 HK 1248218A1
Authority
HK
Hong Kong
Prior art keywords
receptor
muscarinic
agonists
spirocyclic compounds
spirocyclic
Prior art date
Application number
HK18107567.8A
Other languages
English (en)
Inventor
邁爾斯‧斯圖爾特‧康格里夫
蓋爾斯‧艾伯特‧布朗
本杰明‧杰拉爾德‧特漢
馬克‧皮克沃斯
朱莉‧伊萊恩‧坎斯菲爾德
Original Assignee
赫普泰雅治療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赫普泰雅治療有限公司 filed Critical 赫普泰雅治療有限公司
Publication of HK1248218A1 publication Critical patent/HK1248218A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK18107567.8A 2015-03-19 2018-06-11 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物 HK1248218A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504675.8A GB201504675D0 (en) 2015-03-19 2015-03-19 Pharmaceutical compounds
PCT/GB2016/050771 WO2016147011A1 (en) 2015-03-19 2016-03-21 Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor

Publications (1)

Publication Number Publication Date
HK1248218A1 true HK1248218A1 (zh) 2018-10-12

Family

ID=53052080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107567.8A HK1248218A1 (zh) 2015-03-19 2018-06-11 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物

Country Status (11)

Country Link
US (1) US10167284B2 (zh)
EP (1) EP3271358B1 (zh)
JP (1) JP6675415B2 (zh)
CN (1) CN107406449B (zh)
AU (1) AU2016231951B9 (zh)
CA (1) CA2979009C (zh)
DK (1) DK3271358T3 (zh)
ES (1) ES2852753T3 (zh)
GB (1) GB201504675D0 (zh)
HK (1) HK1248218A1 (zh)
WO (1) WO2016147011A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402405QA (en) 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) * 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (zh) 2017-10-24 2019-06-16 美商歐樂根公司 烯胺及烯胺的非鏡像選擇性還原
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
WO2019183636A1 (en) * 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
PE20221454A1 (es) 2019-10-09 2022-09-21 Novartis Ag Derivados de 2-azaespiro[3.4]octano como agonistas de m4
AU2020361735B2 (en) * 2019-10-09 2024-04-18 Novartis Ag 2-azaspiro(3.4)octane derivatives as M4 agonists
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2206699A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
KR20080087841A (ko) * 2005-12-22 2008-10-01 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체의 조절제
US8673931B2 (en) * 2009-01-26 2014-03-18 Abraham Fisher Bicyclic heterocyclic spiro compounds
SG11201402405QA (en) * 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
US9266857B2 (en) * 2012-09-18 2016-02-23 Heptares Therapeutics Limited Bicyclic AZA compounds as muscarinic M1 receptor agonists
KR102352388B1 (ko) 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
DK3271358T3 (da) 2021-02-08
EP3271358B1 (en) 2020-11-18
WO2016147011A1 (en) 2016-09-22
US10167284B2 (en) 2019-01-01
JP2018508562A (ja) 2018-03-29
GB201504675D0 (en) 2015-05-06
AU2016231951A1 (en) 2017-09-28
AU2016231951B2 (en) 2020-04-09
CA2979009A1 (en) 2016-09-22
ES2852753T3 (es) 2021-09-14
CN107406449A (zh) 2017-11-28
EP3271358A1 (en) 2018-01-24
JP6675415B2 (ja) 2020-04-01
US20180072727A1 (en) 2018-03-15
CN107406449B (zh) 2020-11-10
AU2016231951B9 (en) 2020-04-16
CA2979009C (en) 2023-09-12

Similar Documents

Publication Publication Date Title
HK1248218A1 (zh) 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物
HK1231473A1 (zh) 作為毒蕈碱 和/或 受體激動劑的雙環氮雜化合物
HK1253036A1 (zh) 作為毒蕈碱m1和/或m4受體的激動劑的肟化合物
HK1250160A1 (zh) 毒蕈碱激動劑
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
HK1231382A1 (zh) 毒蕈碱受體激動劑
IL248311B (en) Compounds and preparations as agonists of toll-like receptor 7
HK1250139A1 (zh) 毒蕈碱激動劑
AP2016009485A0 (en) Compounds and compositions as toll-like receptor 7 agonists
HK1250138A1 (zh) 毒蕈碱激動劑
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
IL252311A0 (en) 4-oxo-4,3-dihydro-3,2,1-benzotriazines as G protein-coupled receptor modulators 139
EP3265466A4 (en) Peripheral-anticholinergic muscarinic agonist combination
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
ZA201608823B (en) Processes for the preparation of azd5363 and novel intermediate used therein